In addition, high DUXAP10 expression was closely associated with more advanced tumor stage or grade, earlier lymph node metastasis, and unfavorable OS, PFS, and RFS rates, which provides powerful evidence for the prognostic ability of DUXAP10 in various cancers, such as HCC (Zhu et al., 2018), NSCLC (Wei et al., 2017), RCC (Chen et al., 2020), OC (Zhang et al., 2018), GC (Xu et al., 2018), CRC (Lian et al., 2017), and ESCC (Wang et al., 2018). Here, DUXAP10 is linked to non-small cell lung carcinoma.